Our results provide evidence for a predominant male breast cancer phenotype, characterized by HR expression and a lack of HER2/Topo II-? alterations and CEP17 duplicates.     ///    "Therefore, the impact of anthracycline sensitivity linked to HER2/Topo II-? alterations as found in female breast cancer has low clinical significance for this specific male breast cancer phenotype. "